Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your phone spot eye cancer? app tested for retinoblastoma

NCT ID NCT03016156

Diagnosis Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 16, 2026 · Updated 3 times

Summary

This study tested a smartphone app called CRADLE that uses a photo to detect leukocoria (a white glow in the pupil), which can be a sign of retinoblastoma, cataracts, or glaucoma. Researchers planned to compare the app's accuracy to a standard eye exam in children with these conditions. However, the study was terminated early after enrolling only 1 participant, so no reliable conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Smartphone application (CRADLE)
What this could lead to
If successful, this app could help parents and doctors spot early signs of eye cancer in children using a smartphone, leading to faster diagnosis.
What could go wrong
The study was terminated with only 1 participant, so we have very little data. The app may not be accurate enough to replace standard exams, and results may not apply to all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1 person

The number who actually took part.

Started

Mar 2018

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 7 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria - Stratum I: * Patient has been diagnosed with congenital or infantile cataracts, congenital glaucoma, or retinoblastoma, and is scheduled for a visit with an ophthalmologist at St. Jude Children's Research Hospital or University of Tennessee Hamilton Eye Institute. * Patient with retinoblastoma is newly diagnosed, or has received \< 2 cycles of chemoreductive therapy, and has not undergone enucleation. * Patient with cataracts or glaucoma has not received any prior therapy. Inclusion Criteria - Stratum II: * Patient without prior diagnosis has been referred for ophthalmological evaluation, including leukocoria or other conditions. Inclusion Criteria - Stratum III: * Patient with retinoblastoma undergoing ocular salvage treatment. Exclusion Criteria * Prior treatment for cataracts or glaucoma * Inability or unwillingness of research participant or legal guardian to consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataracts infantile are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cataract congenital glaucoma glaucoma 3A retinoblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataracts infantile Glaucoma, congenital Leucocoria Retinoblastoma

Contacts and locations

Locations

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105-2794, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.